(Q37427254)

20 August 2017

1 reference

title

Implementing treatment guidelines for type 2 diabetes in primary care (English)

1 reference

20 August 2017

0 references

Stephen Brunton

1

1 reference

20 August 2017

language of work or name

English

0 references

publication date

1 March 2009

1 reference

20 August 2017

published in

Postgraduate Medicine

1 reference

20 August 2017

volume

121

1 reference

20 August 2017

issue

2

1 reference

20 August 2017

page(s)

125-138

1 reference

Standards of medical care in diabetes--2008.

20 August 2017

cites work

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2009.03.1985

Regression of carotid atherosclerosis by control of postprandial hyperglycemia in type 2 diabetes mellitus.

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2009.03.1985

Reduction in the Incidence of Type 2 Diabetes with Lifestyle Intervention or Metformin

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2009.03.1985

Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2009.03.1985

Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2009.03.1985

Management of hyperglycemia in type 2 diabetes: A consensus algorithm for the initiation and adjustment of therapy: a consensus statement from the American Diabetes Association and the European Association for the Study of Diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2009.03.1985

High blood glucose concentration is a risk factor for mortality in middle-aged nondiabetic men. 20-year follow-up in the Whitehall Study, the Paris Prospective Study, and the Helsinki Policemen Study

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2009.03.1985

Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2009.03.1985

Transitioning pharmacologic therapy from oral agents to insulin for type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2009.03.1985

Effect of Rosiglitazone on the Risk of Myocardial Infarction and Death from Cardiovascular Causes

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2009.03.1985

The treat-to-target trial: randomized addition of glargine or human NPH insulin to oral therapy of type 2 diabetic patients

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2009.03.1985

Insulin detemir: from concept to clinical experience

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2009.03.1985

Efficacy and safety of incretin therapy in type 2 diabetes: systematic review and meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2009.03.1985

Systematic Review: Comparative Effectiveness and Safety of Oral Medications for Type 2 Diabetes Mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2009.03.1985

Pramlintide as an adjunct to insulin therapy improves long-term glycemic and weight control in patients with type 2 diabetes: a 1-year randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2009.03.1985

Effect of the dipeptidyl peptidase-4 inhibitor sitagliptin as monotherapy on glycemic control in patients with type 2 diabetes.

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2009.03.1985

Effect of a multifactorial intervention on mortality in type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2009.03.1985

Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2009.03.1985

Effects of intensive glucose lowering in type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2009.03.1985

Glucose control and vascular complications in veterans with type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2009.03.1985

Management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: update regarding thiazolidinediones: a consensus statement from the American Diabetes Association and the European Association for th

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2009.03.1985

Lower within-subject variability of fasting blood glucose and reduced weight gain with insulin detemir compared to NPH insulin in patients with type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2009.03.1985

A randomised, 52-week, treat-to-target trial comparing insulin detemir with insulin glargine when administered as add-on to glucose-lowering drugs in insulin-naive people with type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2009.03.1985

Basal insulin therapy in type 2 diabetes: 28-week comparison of insulin glargine (HOE 901) and NPH insulin

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2009.03.1985

A multicenter, randomized, open-label, comparative, two-period crossover trial of preference, efficacy, and safety profiles of a prefilled, disposable pen and conventional vial/syringe for insulin injection in patients with type 1 or 2 diabetes mell

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2009.03.1985

FlexPen: addressing issues of confidence and convenience in insulin delivery

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2009.03.1985

Quality of life, treatment satisfaction, and treatment preference associated with use of a pen device delivering a premixed 70/30 insulin aspart suspension (aspart protamine suspension/soluble aspart) versus alternative treatment strategies

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2009.03.1985

Pay-for-Performance Contracts in Diabetes Care

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2009.03.1985

Internet resources to improve health care for patients with diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2009.03.1985

A study of certified diabetes educators: influences and barriers.

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2009.03.1985

Translating the chronic care model into the community: results from a randomized controlled trial of a multifaceted diabetes care intervention

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2009.03.1985

Implementing the chronic care model for improvements in diabetes care and education in a rural primary care practice

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2009.03.1985

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2009.03.1985

Glycemic control and type 2 diabetes mellitus: the optimal hemoglobin A1c targets. A guidance statement from the American College of Physicians

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2009.03.1985

Intensive glycemic control in the ACCORD and ADVANCE trials

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2009.03.1985

21 January 2018

Identifiers

DOI

10.3810/PGM.2009.03.1985

1 reference

20 August 2017

1 reference